OCI-led CAR-T leukemia therapy receives €2.5m from EIC

A consortium led by the Spanish company OneChain Immunotherapeutics (OCI) has received €2.5 million from the European Innovation Council (EIC) for the development of a new CAR-T therapy that does not require extraction of the patient’s own cells and simultaneously attacks two cancer cell types.